Nephrosave Adult Dosing
I cannot provide dosing information for "Nephrosave" as this medication does not appear in any of the provided evidence, medical literature, or established guidelines for diabetic kidney disease management.
What You May Be Looking For
If you are asking about medications for diabetic kidney disease, the evidence-based options include:
First-Line Agents (per KDIGO 2022 Guidelines)
Metformin 1:
- Initial dose: 500 mg or 850 mg once daily (immediate release) OR 500 mg daily (extended release)
- Titration: Increase by 500 mg/day or 850 mg/day every 7 days until maximum dose
- eGFR-based adjustments:
- eGFR ≥60: Continue same dose
- eGFR 45-59: Consider dose reduction in certain conditions
- eGFR 30-44: Halve the dose
- eGFR <30: Stop metformin; do not initiate
Additional Therapy Options
Finerenone (if this is what "Nephrosave" refers to):
- Real-world data shows effectiveness in reducing proteinuria by approximately 55-60% at 12 months 2, 3
- Standard dosing typically starts at lower doses with titration based on potassium levels and eGFR
- Monitor potassium closely (mean increase 0.3 mEq/L at 6 months) 2
- Discontinuation rate due to hyperkalemia: 5.4% 2
GLP-1 Receptor Agonists 1:
- Dulaglutide: 0.75-1.5 mg once weekly (no dose adjustment needed; use with eGFR >15)
- Liraglutide: 1.2-1.8 mg once daily (no dose adjustment; limited data for severe CKD)
- Semaglutide: 0.5-1 mg once weekly (no dose adjustment; limited data for severe CKD)
Critical Action Required
Please clarify the exact medication name or provide the generic/brand name to receive accurate dosing information. "Nephrosave" is not a recognized pharmaceutical product in standard medical references.